Millennium Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$164M Buy
1,247,447
+804,581
+182% +$107M 0.07% 263
2025
Q4
$62.8M Sell
442,866
-534,344
-55% -$77.4M 0.03% 658
2025
Q3
$137M Sell
977,210
-217,009
-18% -$29.4M 0.06% 304
2025
Q2
$150M Buy
1,194,219
+617,629
+107% +$70.8M 0.07% 244
2025
Q1
$63.8M Buy
576,590
+157,878
+38% +$20M 0.03% 593
2024
Q4
$57.2M Buy
418,712
+105,945
+34% +$13.1M 0.03% 706
2024
Q3
$36M Buy
312,767
+125,284
+67% +$17.2M 0.02% 1056
2024
Q2
$25.8M Sell
187,483
-267,737
-59% -$36.7M 0.01% 1285
2024
Q1
$62.8M Sell
455,220
-233,736
-34% -$31.9M 0.03% 692
2023
Q4
$90.8M Sell
688,956
-579,310
-46% -$66.7M 0.04% 461
2023
Q3
$143M Buy
1,268,266
+418,008
+49% +$44M 0.07% 222
2023
Q2
$80.2M Buy
850,258
+281,983
+50% +$27.6M 0.04% 463
2023
Q1
$57.5M Sell
568,275
-272,065
-32% -$28.3M 0.03% 608
2022
Q4
$100M Buy
840,340
+267,284
+47% +$31.3M 0.06% 373
2022
Q3
$60.9M Buy
573,056
+210,383
+58% +$21.3M 0.04% 568
2022
Q2
$35.4M Sell
362,673
-137,454
-27% -$12.7M 0.02% 850
2022
Q1
$46.9M Sell
500,127
-60,870
-11% -$5.16M 0.02% 734
2021
Q4
$47.8M Buy
560,997
+69,753
+14% +$6.42M 0.02% 751
2021
Q3
$47.1M Buy
491,244
+369,733
+304% +$34.9M 0.03% 662
2021
Q2
$11.8M Buy
+121,511
New +$11.6M 0.01% 1708
2021
Q1
Sell
-225,156
Closed -$23.6M 6316
2020
Q4
$21.6M Buy
225,156
+182,520
+428% +$17.6M 0.02% 1008
2020
Q3
$4.1K Sell
42,636
-16,514
-28% -$1.91M 0.01% 2019
2020
Q2
$7.22M Sell
59,150
-57,650
-49% -$6.37M 0.01% 1460
2020
Q1
$10.1M Sell
116,800
-269,258
-70% -$26.4M 0.02% 847
2019
Q4
$41.5M Buy
386,058
+109,006
+39% +$11.4M 0.05% 455
2019
Q3
$25M Buy
277,052
+73,342
+36% +$6.85M 0.04% 638
2019
Q2
$17.2M Sell
203,710
-356,238
-64% -$29.3M 0.03% 877
2019
Q1
$49.3M Buy
559,948
+539,208
+2,600% +$45.1M 0.07% 349
2018
Q4
$1.48M Sell
20,740
-337,795
-94% -$32.4M ﹤0.01% 2385
2018
Q3
$44.1M Buy
358,535
+331,346
+1,219% +$37.6M 0.05% 463
2018
Q2
$2.67M Sell
27,189
-100,726
-79% -$9.02M ﹤0.01% 2207
2018
Q1
$10.6M Sell
127,915
-406,651
-76% -$34.3M 0.01% 1287
2017
Q4
$41.5M Buy
534,566
+417,661
+357% +$28.5M 0.06% 497
2017
Q3
$7.16M Buy
+116,905
New +$6.17M 0.01% 1463
2017
Q1
Sell
-1,335,798
Closed -$51.7M 3725
2016
Q4
$51.7M Buy
1,335,798
+1,227,830
+1,137% +$55.6M 0.11% 251
2016
Q3
$5.47M Sell
107,968
-506,608
-82% -$25.2M 0.01% 1284
2016
Q2
$27.9M Sell
614,576
-474,339
-44% -$21.8M 0.06% 386
2016
Q1
$43.1M Buy
1,088,915
+31,292
+3% +$1.24M 0.11% 218
2015
Q4
$59.8M Sell
1,057,623
-267,751
-20% -$13.6M 0.13% 182
2015
Q3
$52.7M Buy
1,325,374
+168,487
+15% +$8.14M 0.1% 228
2015
Q2
$55.3M Sell
1,156,887
-315,986
-21% -$13.4M 0.1% 237
2015
Q1
$58.5M Buy
1,472,873
+251,207
+21% +$8.99M 0.11% 211
2014
Q4
$27.3M Buy
1,221,666
+879,740
+257% +$16.7M 0.06% 459
2014
Q3
$5.36M Sell
341,926
-67,015
-16% -$1M 0.01% 1254
2014
Q2
$6.07M Buy
+408,941
New +$5.77M 0.02% 1088
2014
Q1
Sell
-830,874
Closed -$7.76M 3744
2013
Q4
$7.76M Buy
830,874
+765,874
+1,178% +$7.47M 0.02% 866
2013
Q3
$736K Sell
65,000
-15,819
-20% -$217K ﹤0.01% 2310
2013
Q2
$1.08M Buy
+80,819
New +$993K ﹤0.01% 1922

Other funds holding NBIX

Millennium Management's NBIX Position: Q1 2026 in Review

Millennium Management increased its Neurocrine Biosciences (NBIX) stake by 182% in Q1 2026, buying an estimated $107M and bringing the position to 1,247,447 shares worth $164M. The position accounts for 0.07% of the portfolio, ranked #263.

Millennium Management first reported a position in NBIX in Q2 2013 and has held it in 48 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Millennium Management held 1,247,447 shares of Neurocrine Biosciences worth $164M as of Q1 2026.
  • Millennium Management bought 804,581 Neurocrine Biosciences shares in Q1 2026, an estimated $107M.
  • Neurocrine Biosciences made up 0.07% of Millennium Management's portfolio in Q1 2026, its #263 holding.
  • Millennium Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 48 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.